nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0419	0.0632	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Endothelin Pathways—ADCY10—nephrolithiasis	0.027	0.0407	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0171	0.0258	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0159	0.024	CbGpPWpGaD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—PTH—nephrolithiasis	0.0158	0.0239	CbGpPWpGaD
Dextroamphetamine—Injury—Hydrochlorothiazide—nephrolithiasis	0.0135	0.04	CcSEcCtD
Dextroamphetamine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.0133	0.0396	CcSEcCtD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0126	0.019	CbGpPWpGaD
Dextroamphetamine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0364	CcSEcCtD
Dextroamphetamine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0122	0.0362	CcSEcCtD
Dextroamphetamine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.0117	0.0348	CcSEcCtD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0115	0.0174	CbGpPWpGaD
Dextroamphetamine—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0335	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0112	0.0169	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0112	0.0169	CbGpPWpGaD
Dextroamphetamine—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.0111	0.0331	CcSEcCtD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0107	0.0161	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0106	0.016	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0103	0.0155	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0103	0.0155	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0102	0.0154	CbGpPWpGaD
Dextroamphetamine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00985	0.0292	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00976	0.029	CcSEcCtD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00949	0.0143	CbGpPWpGaD
Dextroamphetamine—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00945	0.0281	CcSEcCtD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00942	0.0142	CbGpPWpGaD
Dextroamphetamine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.0094	0.0279	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00934	0.0277	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00927	0.0275	CcSEcCtD
Dextroamphetamine—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00914	0.0271	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00825	0.0124	CbGpPWpGaD
Dextroamphetamine—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00809	0.024	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00778	0.0117	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00778	0.0117	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00774	0.0117	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00772	0.0116	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00755	0.0114	CbGpPWpGaD
Dextroamphetamine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00731	0.0217	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00727	0.011	CbGpPWpGaD
Dextroamphetamine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00723	0.0215	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00723	0.0109	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00723	0.0109	CbGpPWpGaD
Dextroamphetamine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00698	0.0207	CcSEcCtD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00691	0.0104	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00691	0.0104	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00687	0.0104	CbGpPWpGaD
Dextroamphetamine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00685	0.0203	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.00684	0.0103	CbGpPWpGaD
Dextroamphetamine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00681	0.0202	CcSEcCtD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00669	0.0101	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—RGS14—nephrolithiasis	0.0066	0.00995	CbGpPWpGaD
Dextroamphetamine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00658	0.0195	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00645	0.00972	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0064	0.00965	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0064	0.00965	CbGpPWpGaD
Dextroamphetamine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00634	0.0188	CcSEcCtD
Dextroamphetamine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00632	0.0188	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00628	0.00947	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.0062	0.0184	CcSEcCtD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00612	0.00923	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00612	0.00923	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00608	0.0181	CcSEcCtD
Dextroamphetamine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00593	0.0176	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00588	0.0175	CcSEcCtD
Dextroamphetamine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00579	0.0172	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—PTH—nephrolithiasis	0.00574	0.00866	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.0057	0.0086	CbGpPWpGaD
Dextroamphetamine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.0055	0.0163	CcSEcCtD
Dextroamphetamine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00542	0.0161	CcSEcCtD
Dextroamphetamine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.0054	0.016	CcSEcCtD
Dextroamphetamine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00535	0.0159	CcSEcCtD
Dextroamphetamine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00528	0.0157	CcSEcCtD
Dextroamphetamine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00524	0.0156	CcSEcCtD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00524	0.00789	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00524	0.00789	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00522	0.00787	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00522	0.00787	CbGpPWpGaD
Dextroamphetamine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.0052	0.0154	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00497	0.0148	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00491	0.0074	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00487	0.00734	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00487	0.00734	CbGpPWpGaD
Dextroamphetamine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00483	0.0143	CcSEcCtD
Dextroamphetamine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00481	0.0143	CcSEcCtD
Dextroamphetamine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00481	0.0143	CcSEcCtD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00464	0.00699	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00464	0.00699	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADCY10—nephrolithiasis	0.00459	0.00691	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00448	0.0133	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—DGKH—nephrolithiasis	0.00446	0.00672	CbGpPWpGaD
Dextroamphetamine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00436	0.013	CcSEcCtD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00436	0.00657	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00434	0.00654	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00431	0.0065	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00431	0.0065	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00431	0.00649	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00431	0.00649	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00416	0.0124	CcSEcCtD
Dextroamphetamine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00402	0.0119	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00395	0.00596	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00395	0.00596	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RGS14—nephrolithiasis	0.0039	0.00588	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0039	0.00588	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00387	0.00584	CbGpPWpGaD
Dextroamphetamine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00387	0.0115	CcSEcCtD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00384	0.00579	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00384	0.00579	CbGpPWpGaD
Dextroamphetamine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00383	0.0114	CcSEcCtD
Dextroamphetamine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00383	0.0114	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00381	0.00575	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00381	0.00575	CbGpPWpGaD
Dextroamphetamine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00381	0.0113	CcSEcCtD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00378	0.0057	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00368	0.00554	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00368	0.00554	CbGpPWpGaD
Dextroamphetamine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00361	0.0107	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00355	0.00535	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00351	0.00529	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00351	0.00529	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00346	0.00522	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.0034	0.00513	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00336	0.00506	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00328	0.00494	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00328	0.00494	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PTH—nephrolithiasis	0.00325	0.00489	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00322	0.00486	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00315	0.00475	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00311	0.00469	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00311	0.00469	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTH—nephrolithiasis	0.00295	0.00444	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00282	0.00425	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00281	0.00424	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0028	0.00422	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00266	0.00401	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00266	0.00401	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00263	0.00397	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DGKH—nephrolithiasis	0.00263	0.00397	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00262	0.00395	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.0025	0.00377	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00247	0.00373	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00247	0.00373	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00244	0.00367	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00236	0.00355	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00236	0.00355	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.0022	0.00332	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.0022	0.00332	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00219	0.0033	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00219	0.0033	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00216	0.00326	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00209	0.00315	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00195	0.00294	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00195	0.00294	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CHRM3—nephrolithiasis	0.0019	0.00287	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00185	0.00279	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—RGS14—nephrolithiasis	0.00184	0.00277	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00176	0.00266	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTH—nephrolithiasis	0.00174	0.00263	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—RGS14—nephrolithiasis	0.00167	0.00252	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00163	0.00246	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00159	0.0024	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00156	0.00235	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—RGS14—nephrolithiasis	0.00148	0.00224	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTH—nephrolithiasis	0.00145	0.00219	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00141	0.00213	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTH—nephrolithiasis	0.00129	0.00195	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00124	0.00187	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADCY10—nephrolithiasis	0.00116	0.00175	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DGKH—nephrolithiasis	0.00113	0.0017	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.0011	0.00166	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADCY10—nephrolithiasis	0.00103	0.00155	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DGKH—nephrolithiasis	0.001	0.00151	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RGS14—nephrolithiasis	0.000986	0.00149	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000898	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RGS14—nephrolithiasis	0.000876	0.00132	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SPP1—nephrolithiasis	0.000874	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PTH—nephrolithiasis	0.000821	0.00124	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CHRM3—nephrolithiasis	0.000815	0.00123	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000797	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTH—nephrolithiasis	0.000746	0.00112	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PTH—nephrolithiasis	0.000729	0.0011	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000724	0.00109	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DGKH—nephrolithiasis	0.000666	0.001	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000666	0.001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTH—nephrolithiasis	0.000662	0.000999	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000634	0.000956	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DGKH—nephrolithiasis	0.000592	0.000892	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000592	0.000892	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000565	0.000852	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CHRM3—nephrolithiasis	0.000482	0.000726	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000481	0.000725	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000481	0.000725	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTH—nephrolithiasis	0.00044	0.000664	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000428	0.000645	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTH—nephrolithiasis	0.000391	0.00059	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000343	0.000516	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.00031	0.000467	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SPP1—nephrolithiasis	0.000221	0.000333	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SPP1—nephrolithiasis	0.000196	0.000296	CbGpPWpGaD
